TY - JOUR
T1 - Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients
AU - Van Der Ende, Marchina E.
AU - Prins, Jan M.
AU - Brinkman, Kees
AU - Keuter, Monique
AU - Veenstra, Jan
AU - Danner, Sven A.
AU - Niesters, Hubert G.M.
AU - Osterhaus, Albert D.M.E.
AU - Schutten, Martin
PY - 2003/7
Y1 - 2003/7
N2 - Objective: To assess the clinical, immunological and virological response and the emergence of resistance towards antiretroviral therapy (ART) in a cohort of HIV-2-infected patients. Design: Observational study. Patients: HIV-2-infected patients residing in the Netherlands. Results: From 1995 to 2001 seven patients failed various ART regimens. The resistance mutations were analysed retrospectively. Development of mutations proved to be similar to that observed in HIV-1-infected patients, with the exception of a higher occurrence of the Q151M mutation within the reverse transcriptase gene. In a prospective study, comprising 13 consecutive naive HIV-2-infected patients, all patients achieved plasma HIV-2-RNA suppression below the detection limit (500 copies/ml). The antiretroviral regimen consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) and indinavir, with a boosting dose of ritonavir; the median follow-up was 91 weeks. Two patients experienced a temporary virological rebound, while at the same time therapeutic drug monitoring showed sub-therapeutic plasma levels of indinavir. Conclusion: Sustained viral suppression in HIV-2-infected patients can be achieved using an antiretroviral regimen of two NRTIs and boosted indinavir or lopinavir.
AB - Objective: To assess the clinical, immunological and virological response and the emergence of resistance towards antiretroviral therapy (ART) in a cohort of HIV-2-infected patients. Design: Observational study. Patients: HIV-2-infected patients residing in the Netherlands. Results: From 1995 to 2001 seven patients failed various ART regimens. The resistance mutations were analysed retrospectively. Development of mutations proved to be similar to that observed in HIV-1-infected patients, with the exception of a higher occurrence of the Q151M mutation within the reverse transcriptase gene. In a prospective study, comprising 13 consecutive naive HIV-2-infected patients, all patients achieved plasma HIV-2-RNA suppression below the detection limit (500 copies/ml). The antiretroviral regimen consisted of two nucleoside reverse transcriptase inhibitors (NRTIs) and indinavir, with a boosting dose of ritonavir; the median follow-up was 91 weeks. Two patients experienced a temporary virological rebound, while at the same time therapeutic drug monitoring showed sub-therapeutic plasma levels of indinavir. Conclusion: Sustained viral suppression in HIV-2-infected patients can be achieved using an antiretroviral regimen of two NRTIs and boosted indinavir or lopinavir.
KW - Antiretroviral drug resistance
KW - Antiretroviral therapy
KW - HIV-2
KW - HIV-2 RNA
KW - Nucleoside analogues
KW - Protease inhibitors
UR - http://www.scopus.com/inward/record.url?scp=0043033106&partnerID=8YFLogxK
U2 - https://doi.org/10.1097/00002030-200317003-00008
DO - https://doi.org/10.1097/00002030-200317003-00008
M3 - Article
C2 - 14565610
SN - 0269-9370
VL - 17
SP - S55-S61
JO - AIDS
JF - AIDS
IS - SUPPL. 3
ER -